motavizumab (MEDI-524)

BIOLOGICAL2 trials

Sponsors

MedImmune LLC

Conditions

Motavizumab Administration for a Second Season for RSV ProphylaxisRespiratory Syncytial Virus Infections

Phase 1

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

CompletedNCT00113490

MedImmune LLCMotavizumab Administration for a Second Season for RSV Prophylaxis

Start: 2005-05-31End: 2006-02-28Updated: 2013-05-22

Phase 3

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

CompletedNCT00129766

MedImmune LLCRespiratory Syncytial Virus Infections

Start: 2004-11-30End: 2006-05-31Updated: 2013-08-28